2OW.MU Stock Analysis
2O
Uncovered
Silk Road Medical Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 414 full-time employees. The company went IPO on 2019-04-04. The firm has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The firm's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. The company markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.